The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.

ABSTRACT:

Background

The novel nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone holds promise to be safe and efficient in the treatment of patients with heart failure and/or chronic kidney disease. However, its effects on vascular function remain elusive.

Purpose

The aim of this study was to determine the functional effect of selective MR antagonism by finerenone in vascular cells in vitro and the effect on vascular remodeling following acute vascular injury in vivo.

Methods and results

In vitro, finerenone dose-dependently reduced aldosterone-induced smooth muscle cell (SMC) proliferation, as quantified by BrdU incorporation, and prevented aldosterone-induced endothelial cell (EC) apoptosis, as measured with a flow cytometry based caspase 3/7 activity assay.

SUBMITTER: Dutzmann J 

PROVIDER: S-EPMC5605005 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature